NeuroRx Says COVID-19 Drug Improves Survival If Overstretched ICUs Excluded

Will Seek EUA Shortly

Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut.

ICU Covid — NeuroRx argues that ICUs overwhelmed by COVID-19 cases should be excluded from the trial - but the US FDA may not agree • Source: Getty Images

NeuroRx believes it has a breakthrough treatment for critically ill COVID-19 patients, after unveiling Phase IIb/III data for its novel therapy Zyesami (aviptadil acetate) earlier this week.

The small, privately held biopharma company unveiled trial data on 29 March which showed that the vasoactive intestinal polypeptide (VIP) therapy met its primary endpoint in helping patients recover from respiratory

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

20 May 2025

• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

19 May 2025

• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.